Principal Investigators
Position Group Leader of the Laboratory of Macromolecules and Interactomes
Research fields Human Interactomics, L1 Retrotransposons, and RNA Processing
  • Research Profile
  • Selected Publications
  • John LaCava earned a B.S. degree in Biotechnology from the University of California, Davis (2000). He subsequently earned his Ph.D. in Molecular Genetics (2005) from The University of Edinburgh, Scotland, where he studied mechanisms of post-transcriptional gene regulation with Prof. David Tollervey. Thereafter, John trained in structural proteomic research methods within the Mass Spectrometry of Biomacromolecules group at the University of Amsterdam; and as an EMBO long term post-doctoral fellow, he studied pre-mRNA splicing regulation at the Centre for Genomic Regulation in Barcelona, Spain. In 2008, John returned to the USA to join the Laboratory of Cellular and Structural Biology at The Rockefeller University. Working with Profs. Michael Rout, Brian Chait, and others in the NIH-funded National Center for Dynamic Interactome Research, John focussed on developing methods to improve protein interactions studies. In 2016 John was promoted to the rank of Research Assistant Professor at The Rockefeller University and also joined the NIH-funded Center for Systems Biology of Retrotransposition, earning him a joint appointment as Visiting Assistant Professor at NYU Langone Health. In 2019 John was promoted to Research Associate Professor at The Rockefeller University, and was recruited to join ERIBA as a Principal Investigator, where he leads the Laboratory of Macromolecules and Interactomes.


    John’s group develops protein-centric methods to study the contributions of dysregulated macromolecular interactions to human diseases, including those related to ageing. Among these, the group study the molecular (patho)physiology of LINE-1 ribonucleoproteins in cancer and ageing.

    • Winczura K, Domanski M, LaCava J. (2020) Affinity Proteomic Analysis of the Human Exosome and Its Cofactor Complexes. Methods in Molecular Biology.  
    • Dou Y, Kalmykova S, Pashkova M, Oghbaie M, Jiang H, Molloy KR, Chait BT, Rout MP, Fenyö D, Jensen TH, Altukhov I, LaCava J. (2020) Affinity proteomic dissection of the human nuclear cap-binding complex interactome. Nucleic Acids Research.  
    • Dou Y, Barbosa I, Jiang H, Iasillo C, Molloy KR, Schulze WM, Cusack S, Schmid M, Le Hir H, LaCava J, Jensen TH. (2020) NCBP3 positively impacts mRNA biogenesis. Nucleic Acids Research.
    • Carter V, LaCava J, Taylor MS, Liang SY, Mustelin C, Ukadike KC, Bengtsson A, Lood C, Mustelin T. (2020) High Prevalence and Disease Correlation of Autoantibodies Against p40 Encoded by Long Interspersed Nuclear Elements in Systemic Lupus Erythematosus. Arthritis Rheumatology.  
    • Ardeljan D, Wang X, Oghbaie M, Taylor MS, Husband D, Deshpande V, Steranka JP, Gorbounov M, Yang WR, Sie B, Larman HB, Jiang H, Molloy KR, Altukhov I, Li Z, McKerrow W, Fenyö D, Burns KH, LaCava J. (2020) LINE-1 ORF2p expression is nearly imperceptible in human cancers. Mobile DNA.  
    • Taylor MS, Altukhov I, Molloy KR, Mita P, Jiang H, Adney EM, Wudzinska A, Badri S, Ischenko D, Eng G, Burns KH, Fenyö D, Chait BT, Alexeev D, Rout MP, Boeke JD & LaCava J. (2018) Dissection of affinity captured LINE-1 macromolecular complexes. eLife.
    • Domanski M, Upla P, Rice WJ, Molloy KR, Ketaren NE, Stokes DL, Jensen TH, Rout MP & LaCava J. (2016) Purification and Analysis of Endogenous Human RNA Exosome Complexes. RNA.
    • Hakhverdyan ZM, Domanski L. Hough AA, Oroskar AR, Oroskar DJ, Dilworth KR, Molloy V, Sherman JD, Aitchison BT, Chait, Jensen TH, Rout MP & LaCava J. (2015) Rapid, Optimized Interactomic Screening. Nature Methods.  
    • Taylor MS, LaCava J, Mita P, Molloy KR, Huang CR, Li D, Adney EM, Jiang H, Burns KH, Chait BT, Rout MP, Boeke JD & Dai.L. (2013) Affinity proteomics reveals human host factors implicated in discrete stages of LINE-1 retrotransposition. Cell.
Share this:
Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now